Lamotrigine (All indications)

Severe cognitive developmental delay (Mental retardation) (> 6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12727
R48006		 Bjørk (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 1.34 [0.92;1.95]
excluded (control group) 		27/7,950   16,384/4,463,879 16,411 7,950
ref
S12728
R48009		 Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 0.53 [0.35;0.80] C 27/7,950   139/21,634 166 7,950
ref
Total 1 studies 0.53 [0.35;0.80] 166 7,950
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022Bjørk, 2022 1 0.53[0.35; 0.80]1667,9500%ROB confusion: unclearROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Controls unexposed, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.53[0.35; 0.80]1667,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.53[0.35; 0.80]1667,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 1 Tags Adjustment   - No  - No 0.53[0.35; 0.80]1667,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 1 Controls   - epilepsy indication  - epilepsy indication 0.53[0.35; 0.80]1667,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 1 All studiesAll studies 0.53[0.35; 0.80]1667,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12727

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.34[0.92; 1.95]16,4117,950 -NABjørk (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2022 1 unexposed, sick controlsunexposed, sick controls 0.53[0.35; 0.80]1667,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 10.510.01.0